[
  {
    "question": "Which of the following considered as red flag in multiple sclerosis?",
    "option_a": "(Extensive spinal lesion): Although extensive spinal cord lesions (>3 vertebral segments) are more characteristic of NMOSD, on their own they are not as definitive a red flag for MS in the absence of other atypical features. Option b (Bilateral INO): Bilateral internuclear ophthalmoplegia is a well\u2010recognized manifestation of MS due to medial longitudinal fasciculus involvement and is consistent with MS. Option c (Enhancing lesion more than 3 months/complete ophthalmoplegia): This option is atypical since gadolinium enhancement in MS usually resolves within 4",
    "option_b": "",
    "option_c": "is the correct answer.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question asks about identifying red flag features in multiple sclerosis (MS). Red flags are atypical findings which may suggest alternative diagnoses rather than classic MS. Recognizing these helps avoid misdiagnosis and inappropriate treatment. MS is an immune\u2010mediated demyelinating disorder characterized by lesions in the central nervous system. Typical lesions show gadolinium enhancement that lasts for a few weeks, reflecting an acute inflammatory process. Persistence of enhancement beyond 3 months, as well as unusual clinical features such as complete ophthalmoplegia, is not consistent with the natural evolution of MS lesions and may indicate another pathology such as neuromyelitis optica spectrum disorder (NMOSD), brainstem tumors, or other inflammatory processes. In standard MS, lesions on MRI tend to show resolution of gadolinium enhancement within 4\u20138 weeks. The presence of a lesion that continues to enhance after 3 months is unusual. Similarly, while internuclear ophthalmoplegia (INO) is common in MS, complete ophthalmoplegia is rare and more suggestive of extensive brainstem involvement from another etiology. When atypical findings are encountered, further evaluation is indicated. Differential diagnoses include NMOSD (especially when spinal lesions extend over three vertebral segments), sarcoidosis, lymphoma, or even other infectious/inflammatory conditions. A careful neurologic exam, repeat imaging, and laboratory studies (such as anti\u2010aquaporin 4 antibodies for NMOSD) are essential to differentiate these conditions from MS. In MS, disease modification is based on accurate diagnosis. When red flag features (such as persistent enhancement >3 months or complete ophthalmoplegia) are identified, additional diagnostic testing is warranted before confirming the diagnosis. Management might then shift according to the alternative diagnosis. In patients who are pregnant or lactating, it is critical to select therapies that are safe for the mother and fetus/infant; for example, many MS disease\u2010modifying therapies (DMTs) are contraindicated in pregnancy, so a revision of diagnosis directly influences treatment planning. Option a (Extensive spinal lesion): Although extensive spinal cord lesions (>3 vertebral segments) are more characteristic of NMOSD, on their own they are not as definitive a red flag for MS in the absence of other atypical features. Option b (Bilateral INO): Bilateral internuclear ophthalmoplegia is a well\u2010recognized manifestation of MS due to medial longitudinal fasciculus involvement and is consistent with MS. Option c (Enhancing lesion more than 3 months/complete ophthalmoplegia): This option is atypical since gadolinium enhancement in MS usually resolves within 4\u20138 weeks and complete ophthalmoplegia is uncommon; together, these findings serve as red flags that should prompt re\u2010evaluation of the diagnosis. Hence, option c is the correct answer. \u2022 In typical MS, the gadolinium enhancement of lesions resolves within 4\u20138 weeks, so persistent enhancement is unusual.  \u2022 Bilateral INO is common in MS and supports the diagnosis rather than refuting it.  \u2022 Complete ophthalmoplegia is rare in MS and should prompt consideration of alternative diagnoses. Recent research emphasizes that adherence to the revised McDonald Criteria is vital for diagnosis. Persistent lesion enhancement and unusual brainstem findings are increasingly recognized as red flags. Updated guidelines underscore the requirement for careful differential diagnosis, especially when imaging findings do not conform to the expected typical MS evolution.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following considered as red flag in multiple sclerosis?",
    "option_a": "(Partial myelitis): A classic MS feature and thus not a red flag. Option b (Decreased facial sensation): While it reflects demyelinating involvement of sensory pathways, it is consistent with MS. Option c (Complete ophthalmoplegia): This is atypical for MS because complete paralysis of extraocular muscles is rare and should prompt consideration of alternative diagnoses. Option d (Erectile dysfunction): Although autonomic symptoms can occur in MS, erectile dysfunction is nonspecific and common in many conditions, making it an unreliable red flag. Therefore, option c is correct.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question tests the ability to identify red flag features in MS. In classic MS, presentations are typically focal and limited in scope. Red flags are those signs which are atypical for MS and warrant consideration of other diagnoses. MS leads to focal demyelination resulting in neurological deficits confined to specific tracts or regions. While a partial myelitis (incomplete cord syndrome) is common, a complete ophthalmoplegia implies total paralysis of the extraocular muscles \u2013 indicating a more diffuse or severe brainstem involvement that is not characteristic of typical MS lesions. Patients with MS usually present with partial deficits such as unilateral internuclear ophthalmoplegia or partial sensory loss (eg, decreased facial sensation) due to discrete lesion localization. Complete ophthalmoplegia, however, is unusual and suggests the possibility of alternative conditions such as NMOSD, brainstem infarction, or a compressive lesion. When complete ophthalmoplegia occurs, it is necessary to expand the diagnostic workup, including detailed neuroimaging (MRI of the brainstem), serological studies such as anti\u2010aquaporin 4 antibodies, and a thorough clinical evaluation. Differential diagnoses include NMOSD, ischemic stroke of the brainstem, or other inflammatory, infectious, or neoplastic processes. Correct identification of atypical features is crucial since the management for MS differs significantly from that of other conditions like NMOSD. In questionable cases, avoiding premature initiation of MS-specific DMTs is important. For women who are pregnant or lactating, careful consideration of treatment risk\u2013benefit profiles is essential, and therapies with established safety in pregnancy should be prioritized. Option a (Partial myelitis): A classic MS feature and thus not a red flag. Option b (Decreased facial sensation): While it reflects demyelinating involvement of sensory pathways, it is consistent with MS. Option c (Complete ophthalmoplegia): This is atypical for MS because complete paralysis of extraocular muscles is rare and should prompt consideration of alternative diagnoses. Option d (Erectile dysfunction): Although autonomic symptoms can occur in MS, erectile dysfunction is nonspecific and common in many conditions, making it an unreliable red flag. Therefore, option c is correct. \u2022 MS typically presents with incomplete or focal neurological deficits rather than complete cranial nerve palsies. \u2022 Complete ophthalmoplegia is an alarm sign that should trigger consideration of alternative diagnoses such as NMOSD. \u2022 Always correlate clinical findings with imaging to avoid misdiagnosis. Recent studies and consensus guidelines stress the importance of recognizing atypical features in patients presumed to have MS. These red flags, including complete ophthalmoplegia, are reported in the latest neurology literature and are integral to avoiding misclassification of demyelinating disorders.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following is a feature of optic neuritis due to MS?",
    "option_a": "(Papillitis with papilledema): Incorrect because while papillitis (optic disc swelling) can occur in optic neuritis, papilledema implies raised intracranial pressure and is not characteristic of MS",
    "option_b": "(Bilateral ON): Incorrect, as MS optic neuritis is usually unilateral. Option c (Pain with eye movement, unilateral, central/partial visual blurring, normal disc): Correct, as this constellation of findings is typical of retrobulbar optic neuritis due to MS. Option d (Star shape in the retina): Incorrect, since a macular star is seen in conditions like neuroretinitis or hypertensive retinopathy and is not associated with MS.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuroimmunology",
    "explanation": "The focus of this question is to highlight the typical clinical features of optic neuritis in the setting of MS. Optic neuritis is a common presenting symptom of MS, with specific clinical characteristics that help differentiate it from other causes of optic nerve dysfunction. Optic neuritis in MS is due to inflammation and demyelination of the optic nerve. The inflammatory process usually affects the retrobulbar portion of the nerve, leading to impaired conduction. This results in pain, especially with eye movements, and a central visual defect. Patients with MS-associated optic neuritis often present with unilateral vision loss, pain on ocular movement, and sometimes central scotoma. Classic exam findings include a normal fundus (retrobulbar neuritis) since the inflammation is behind the optic disc. The differential diagnosis for optic neuritis includes ischemic optic neuropathies, neuromyelitis optica spectrum disorders, and compressive lesions. Ancillary tests such as visual evoked potentials, optical coherence tomography (OCT), and MRI help in confirming the diagnosis and excluding other causes. Acute management typically involves high-dose intravenous corticosteroids to reduce inflammation and accelerate visual recovery, followed by an evaluation for MS. In pregnant or lactating women, intravenous steroids (after risk\u2013benefit discussion) may be used, as their use is relatively well-studied in such populations, but careful monitoring is required. Option a (Papillitis with papilledema): Incorrect because while papillitis (optic disc swelling) can occur in optic neuritis, papilledema implies raised intracranial pressure and is not characteristic of MS-related optic neuritis. Option b (Bilateral ON): Incorrect, as MS optic neuritis is usually unilateral. Option c (Pain with eye movement, unilateral, central/partial visual blurring, normal disc): Correct, as this constellation of findings is typical of retrobulbar optic neuritis due to MS. Option d (Star shape in the retina): Incorrect, since a macular star is seen in conditions like neuroretinitis or hypertensive retinopathy and is not associated with MS. \u2022 Pain with eye movement is a hallmark of optic neuritis in MS. \u2022 Most cases of MS optic neuritis are retrobulbar, meaning the optic disc appears normal on funduscopic examination. \u2022 Unilateral involvement is far more common than bilateral involvement in MS. Recent guidelines emphasize the importance of early diagnosis and management of optic neuritis to improve visual outcomes. There is also increasing research into remyelinating therapies and neuroprotection, particularly given the potential for long-term visual sequelae if untreated.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with relapsing remitting MS with no disease activity for two years what is the percentage of Benign MS",
    "option_a": "(5%): Correct. Most epidemiological studies estimate that approximately 5% of patients with relapsing",
    "option_b": "(10%), Option c (15%), and Option d (20%) overestimate the prevalence based on current evidence.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question addresses the epidemiologic concept of benign multiple sclerosis (MS) in patients with relapsing\u2013remitting disease who show no disease activity over a significant period. Benign MS is characterized by minimal disability over the long term. Benign MS is thought to represent a subset of MS patients who exhibit less aggressive immune-mediated demyelination, resulting in minimal neurological damage over extended periods. However, retrospective identification of benign MS is challenging since subclinical progression may occur. Clinically, patients with benign MS may experience fewer relapses and have minimal physical disability after many years. Despite an inactive disease course for a given period (e.g., two years), long-term follow\u2010up is necessary because silent progression might still occur. Differentiating benign MS from truly active MS involves long-term clinical and radiographic follow-up. Differential diagnoses include other demyelinating processes and conditions that mimic MS, but true benign MS is defined retrospectively by minimal accumulation of disability over many years. Even in patients who appear to have benign MS, current treatment guidelines recommend continued close monitoring because disease activity may be subclinical. The decision to de-escalate or modify disease\u2010modifying therapy must take into account the risk of future disability accrual. For pregnant and lactating women, therapeutic choices require additional caution; therapies with known safety profiles in pregnancy should be used if treatment is maintained. Option a (5%): Correct. Most epidemiological studies estimate that approximately 5% of patients with relapsing\u2013remitting MS exhibit a truly benign course with minimal disability over long-term follow-up. Option b (10%), Option c (15%), and Option d (20%) overestimate the prevalence based on current evidence. \u2022 Benign MS, defined by minimal disability over decades, is relatively rare (around 5%).  \u2022 A seemingly inactive disease course over a short term (e.g., 2 years) does not guarantee benignity in the long-term.  \u2022 Long-term vigilance and repeated evaluations are critical for all MS patients. Recent long-term cohort studies indicate that while a subset of relapsing\u2013remitting MS patients may appear benign, ongoing research suggests that subclinical disease activity might still be present. Current guidelines advocate for cautious prognostication and sustained monitoring rather than early treatment withdrawal.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "20 YO female patient Known to have MS On interferone, had Rt sided weakness and managed with Methylprednisolone and improved significantly. Few days later symptoms came again but milder, Next step: (pseudo relapse??)",
    "option_a": "(Change DMT) is inappropriate because changing disease",
    "option_b": "(Urinalysis) is correct as it is a simple, non",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is a chronic demyelinating disease often managed with disease-modifying therapies (DMTs) and acute relapses treated with high-dose corticosteroids. A pseudo-relapse is a transient worsening of symptoms due to external factors (e.g., infections, heat) rather than new inflammatory activity. In a pseudo-relapse, pre-existing demyelinated areas become more dysfunctional due to stressors such as infection (commonly urinary tract infections) or increased body temperature, without new inflammatory demyelination. The trigger (such as a UTI) causes metabolic or conduction block, leading to temporary exacerbation of neurologic deficits. A patient with MS who has had a recent corticosteroid-treated relapse and then develops a recurrence of milder symptoms should prompt evaluation for reversible triggers, particularly infections like UTI, rather than an immediate assumption of a new relapse or breakthrough disease activity. The work-up of a suspected pseudo-relapse includes a history and physical exam aimed at identifying precipitating factors. Urinalysis is essential, as UTIs are common in MS patients and can precipitate pseudo-relapses. Differential diagnoses include a true relapse (which would usually present with sustained or progressive deficits) and other systemic infections or metabolic disturbances. First-line management in suspected pseudo-relapse is to identify and treat any underlying trigger. Guidelines recommend a simple screen (e.g., urinalysis) for infection. In pregnancy or lactation, careful antibiotic selection is required to avoid teratogenic risks; agents such as nitrofurantoin (avoided near term) or other pregnancy-safe antibiotics may be used pending gestational timing. Option a (Change DMT) is inappropriate because changing disease-modifying therapy is indicated only in the presence of confirmed breakthrough inflammatory activity, not a pseudo-relapse. Option b (Urinalysis) is correct as it is a simple, non-invasive test to detect a urinary tract infection, a common precipitant of pseudo-relapses in MS. 1. Always consider pseudo-relapse in an MS patient with new symptoms, especially soon after a treated relapse. 2. UTIs are a common trigger; a simple urinalysis may help avoid unnecessary escalation of immunotherapy. Recent guidelines emphasize the importance of distinguishing pseudo-relapses from true relapses to prevent overtreatment. Studies continue to support the approach of thoroughly investigating common triggers, particularly infections, before modifying long-term MS management.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "16-year-old patient presented with confusion; MRI attached showing bilateral white matter changing.",
    "option_a": "(ADEM) is correct based on the patient\u2019s age, acute presentation with encephalopathy, and the typical bilateral, diffuse white matter lesions seen on MRI. Options such as primary CNS angiitis or multiple sclerosis are less likely due to differences in age, clinical course, MRI findings, and typical symptomatology.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuroimmunology",
    "explanation": "Acute disseminated encephalomyelitis (ADEM) is a monophasic inflammatory demyelinating disease of the central nervous system, primarily affecting children and adolescents. It typically presents after an infection or immunization with acute encephalopathy and multifocal neurological deficits. ADEM is believed to be an autoimmune response triggered by a preceding antigenic challenge. This results in perivenular inflammation and demyelination throughout the white matter. The widespread inflammatory response causes diffuse lesions seen on MRI. The patient described, a 16-year-old with confusion (encephalopathy) and bilateral white matter changes on MRI, fits the classic profile for ADEM. In contrast to MS, ADEM is usually a single, self-limited episode without relapses, and lesions are often larger, poorly demarcated and symmetric. Differential diagnosis includes multiple sclerosis (which usually presents with well-defined, periventricular, multifocal lesions and a relapsing-remitting course), primary CNS vasculitis (which tends to produce more focal deficits and infarct-like lesions), and infections (which may be ruled out with CSF studies and other lab tests). MRI findings combined with clinical presentation help in distinguishing ADEM from these entities. The first-line treatment for ADEM is high-dose corticosteroids (e.g., intravenous methylprednisolone). If the patient is pregnant or lactating, intravenous steroids remain the mainstay of treatment though dose adjustments and careful monitoring for potential effects on the fetus or neonate are needed. In steroid-refractory cases, intravenous immunoglobulin (IVIG) or plasmapheresis may be considered as second-line therapies. Option a (ADEM) is correct based on the patient\u2019s age, acute presentation with encephalopathy, and the typical bilateral, diffuse white matter lesions seen on MRI. Options such as primary CNS angiitis or multiple sclerosis are less likely due to differences in age, clinical course, MRI findings, and typical symptomatology. 1. ADEM is often preceded by an infection or immunization and is usually a one-time, monophasic illness. 2. Encephalopathy is a key distinguishing feature, rarely seen in the initial presentation of MS. Current studies and consensus guidelines emphasize early high-dose corticosteroid treatment for ADEM, which is associated with improved outcomes. Recent research has also refined neuroimaging criteria to better differentiate ADEM from multiple sclerosis in pediatric and adolescent populations.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case of spastic paraplegia with family hx of MS in brother, mri showed periventricular white matter lesions. What is the gene?",
    "option_a": "SPAST",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Hereditary spastic paraplegia (HSP) refers to a group of inherited disorders characterized primarily by progressive spasticity and weakness of the lower extremities. The most common form is SPG4, associated with mutations in the SPAST gene. Mutations in the SPAST gene lead to defective spastin protein, which is involved in microtubule severing. This impairment disrupts axonal transport and maintenance, particularly in the long corticospinal tracts, leading to spasticity and weakness. Patients with HSP typically present with slowly progressive spastic paraplegia. Occasionally, mild white matter changes may be noted on MRI, which can sometimes mimic MS. A family history of neurologic disorders (such as a relative diagnosed with MS) can further complicate the clinical picture, but genetic testing and careful clinical evaluation help differentiate the two. The diagnostic work-up for HSP includes a detailed family history, genetic testing (commonly for SPAST mutations in SPG4), and neuroimaging to evaluate both the spinal cord and brain. Differential diagnoses include MS (which is usually relapsing-remitting and has characteristic lesion distribution) and other hereditary disorders causing spastic paraplegia. Management is symptomatic, focusing on spasticity relief (using medications such as baclofen, tizanidine, or diazepam), physical therapy, and assistive devices to maintain mobility. There is no curative treatment as of current guidelines; genetic counseling is recommended for affected families. In pregnant or lactating patients, medications for spasticity are selected carefully to minimize potential risks to the fetus or infant. Option A (SPAST) is correct since mutations in the SPAST gene are the most common cause of autosomal dominant hereditary spastic paraplegia (SPG4). The other options, although not provided here, would not typically be associated with HSP presenting with these clinical and radiologic features. 1. SPG4 due to SPAST gene mutations is the most common cause of hereditary spastic paraplegia in autosomal dominant cases. 2. Mild periventricular white matter changes may be incidental in HSP and must be differentiated from demyelinating conditions like MS. Recent genetic studies continue to validate the role of the SPAST gene in hereditary spastic paraplegia, with ongoing research into biomarkers and potential therapeutic targets. Current guidelines emphasize symptomatic management and regular follow-up for optimizing quality of life.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "A nurse with multiple sclerosis came for a follow up. She's about getting married to a doctor\u2019s friend telling the doctor not to tell him about her disease?",
    "option_a": "Tell him",
    "option_b": "Talk to her and refer to social service",
    "option_c": "respect him and record that on file",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Patient confidentiality is a fundamental ethical and legal principle in medicine. It requires that a physician protect the personal health information of patients unless disclosure is legally mandated or consented to by the patient. While the concept of pathophysiology is typically reserved for disease mechanisms, here it involves understanding the ethical 'mechanism' by which patient-provider trust is maintained through strict confidentiality protocols. In this scenario, the nurse with multiple sclerosis specifically requests that her diagnosis not be disclosed to her fianc\u00e9 (a doctor\u2019s friend). This request is rooted in her right to privacy and autonomy, and clinically it reinforces the principle that health information is confidential, regardless of potential familial or relational interests. Not applicable in a strictly ethical context. However, the approach involves careful documentation of the patient\u2019s wishes and ensuring that discussions around confidentiality are well understood and recorded. First-line management is to respect the patient\u2019s autonomy and confidentiality. The appropriate step is to honor her request to not disclose her diagnosis, while providing education and counseling on the potential implications for personal relationships, if she so desires. Referral to social services or ethics consultation may be considered as a supportive measure if the patient needs further guidance. In pregnancy or lactation-related situations, confidentiality remains paramount and similar ethical principles apply. Option A (Tell him) breaches confidentiality without the patient\u2019s consent and is ethically and legally unsound. Option B (Talk to her and refer to social service) might be an additional supportive measure if the patient needed counseling, but it is not necessary when her explicit request is clear. Option C (Respect her request and record that on file) is the correct and ethically appropriate action, as it upholds patient autonomy and confidentiality. 1. Patient confidentiality is a core principle in all aspects of healthcare and must be maintained unless there is a compelling, legally justified reason to breach it. 2. Documenting patient preferences regarding confidentiality helps protect both the patient and the provider in future care scenarios. Recent guidelines from medical ethics boards and legal standards continue to reinforce the inviolability of patient confidentiality. Studies emphasize that breaches of medical confidentiality can undermine trust in the healthcare system and lead to legal consequences, underscoring the need for clear documentation of patient preferences.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Diagnosed with RRMS and started on DMT then lost follow up and came back with platelet counts of 30 and skin issue (see picture) Which DMT he was on?",
    "option_a": "Alemtuzumab",
    "option_b": "Teriflunomide",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system. In the relapsing\u2010remitting form (RRMS), patients experience episodes of neurological dysfunction with periods of remission. Disease-modifying therapies (DMTs) are used to modify the course of the disease. Alemtuzumab is one such DMT, a monoclonal antibody targeting CD52 on lymphocytes. Alemtuzumab depletes circulating T and B lymphocytes via binding to the CD52 antigen. The subsequent immune reconstitution may lead to secondary autoimmunity. One of the serious complications is immune thrombocytopenia (ITP), where autoantibody-mediated destruction of platelets occurs, leading to severe thrombocytopenia. Skin manifestations can occur as part of autoimmune sequelae or bleeding complications secondary to low platelets. A patient with RRMS on Alemtuzumab who is lost to follow-up and later presents with a very low platelet count (e.g., 30,000/\u00b5L) and associated skin findings (likely petechiae or ecchymoses) should raise suspicion for drug-induced immune thrombocytopenia. Early recognition is critical since severe thrombocytopenia can lead to life-threatening bleeding. The diagnosis involves a detailed history of DMT use, laboratory workup confirming thrombocytopenia, and exclusion of other causes such as idiopathic ITP, other drug-induced thrombocytopenias, or bone marrow suppression. Differential diagnoses include primary ITP, other immunologically mediated cytopenias, and medication effects from other agents like Teriflunomide, which is more hepatotoxic than thrombocytopenic. Management of Alemtuzumab-induced ITP includes cessation of the offending agent and initiation of immunosuppressive therapies such as high-dose corticosteroids and possibly IVIG for severe cases. Long-term monitoring is crucial. In pregnancy and lactation, treatment plans must be tailored since immunosuppressives can pose risks; steroids and IVIG have been used with caution and under guideline recommendations with careful risk-benefit analysis. Option A (Alemtuzumab) is correct because it is uniquely associated with autoimmune ITP and related skin manifestations due to immune reconstitution. Option B (Teriflunomide) is more associated with hepatotoxicity and teratogenicity rather than severe thrombocytopenia and skin issues. 1. Alemtuzumab carries a significant risk of secondary autoimmunity, including immune thrombocytopenia. 2. Close laboratory monitoring, even long after administration, is essential. 3. Recognize that skin manifestations in this context are often a sign of bleeding due to low platelets. Recent clinical guidelines emphasize the importance of regular hematologic monitoring following Alemtuzumab treatment due to the risk of autoimmune complications, including ITP. Updated safety profiles and post-marketing surveillance studies continue to support these recommendations.",
    "exam_year": "2021",
    "exam_type": "Part I",
    "image_url": "page_16.png"
  },
  {
    "question": "Case scenario of a patient with breast cancer, eyes spontaneous nystagmus suggestive of opsoclonus myoclonus, antibody? \u0645\u0643\u0631\u0631",
    "option_a": "anti Ri",
    "option_b": "Anti Yo",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Opsoclonus-myoclonus syndrome is a rare paraneoplastic neurological disorder characterized by chaotic, multidirectional rapid eye movements (opsoclonus) and myoclonic jerks. It can be associated with underlying malignancies, including breast cancer. The syndrome is thought to arise due to an autoimmune response triggered by tumor antigens that cross-react with neuronal antigens. Anti-Ri antibodies (also known as ANNA-2) are frequently implicated in paraneoplastic opsoclonus-myoclonus syndrome, particularly in association with breast cancer and sometimes small cell lung cancer. Patients with breast cancer presenting with spontaneous nystagmus (opsoclonus) and myoclonus should be evaluated for a paraneoplastic etiology. The presence of anti-Ri antibodies supports the diagnosis and helps differentiate it from other causes of abnormal eye movements. The diagnostic workup includes a thorough clinical assessment, imaging studies to evaluate for underlying neoplasms, and serologic testing for appropriate paraneoplastic antibodies (including anti-Ri, anti-Hu, etc.). Differential diagnoses include other paraneoplastic syndromes, metabolic or toxic encephalopathies, and infectious causes. Management involves treating the underlying malignancy and initiating immunotherapy, such as corticosteroids, IVIG, or plasmapheresis. In cases associated with cancer, tumor-directed therapy (such as surgery, chemotherapy, or radiotherapy) is crucial. Pregnancy and lactation considerations include the careful use of immunosuppressive therapies, where agents like IVIG are generally considered safer, and any cancer treatment decisions require multidisciplinary coordination. Option A (anti-Ri) is correct because anti-Ri antibodies are classically associated with opsoclonus-myoclonus syndrome in the setting of breast cancer. Option B (anti-Yo) is more commonly linked with paraneoplastic cerebellar degeneration, particularly in gynecological malignancies, and is less characteristic of opsoclonus-myoclonus. 1. Opsoclonus-myoclonus syndrome should prompt evaluation for an underlying malignancy, especially breast cancer in adults. 2. Anti-Ri antibodies are a key marker in cases associated with this syndrome. 3. Early diagnosis and treatment of the underlying tumor can improve neurological outcomes. Recent studies highlight the importance of antibody testing in guiding the diagnosis of paraneoplastic syndromes. Updated guidelines recommend prompt immunotherapy along with tumor management, underscoring the role of anti-Ri antibody testing in cases with opsoclonus-myoclonus features.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Typical case of stiff man syndrome (history of lordosis\u2026..) asked about dx?",
    "option_a": "stiff man syndrome",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Stiff person syndrome (often called stiff man syndrome) is a rare neurological disorder characterized by progressive muscle rigidity and painful spasms, frequently affecting axial and proximal limb muscles. The condition significantly impacts patient mobility and quality of life. The syndrome is believed to be autoimmune in origin, with antibodies against glutamic acid decarboxylase (anti-GAD) present in a significant number of cases. Anti-GAD antibodies interfere with the production of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, resulting in excessive muscle contraction and rigidity. Patients typically present with stiffness predominantly in the trunk, leading to hyperlordosis (exaggerated lumbar curvature), and may experience superimposed painful spasms often triggered by stress or sudden movement. These features strongly support the diagnosis of stiff person syndrome. Diagnosis is clinical, supported by the detection of anti-GAD antibodies and characteristic findings on electromyography (EMG) showing continuous motor unit activity. Differential diagnoses include tetanus, spasticity from other central causes, and functional movement disorders. Management is tiered. First-line therapy includes GABAergic agents, notably benzodiazepines (e.g., diazepam) to reduce muscle rigidity and spasms. Second-line options include baclofen and immunomodulatory therapies such as IVIG, plasmapheresis, or immunosuppressants for resistant cases. In pregnant or lactating patients, careful dosing and choice of benzodiazepines is warranted, and alternatives like low-dose baclofen can be considered, balancing maternal benefits with fetal/neonatal risks. Option A (stiff man syndrome) is correct, as the clinical description (including hyperlordosis and muscle rigidity) fits well with classic stiff person syndrome. The term 'stiff man syndrome' is an older synonym for stiff person syndrome and is used interchangeably in many clinical texts. 1. A high index of suspicion is needed when encountering truncal rigidity with hyperlordosis. 2. Anti-GAD antibodies are positive in the majority of cases, aiding in the diagnosis. 3. Early symptomatic treatment can improve patient function and reduce complications. Recent research has further elucidated the autoimmune basis of stiff person syndrome and supported the use of IVIG in patients with refractory symptoms. Ongoing studies are evaluating long-term outcomes with newer immunomodulatory strategies.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Female patient came in with encephalitis (history of seizure, fever, psychosis). What's the antibody?",
    "option_a": "Anti-NMDA (the Common cause of limbus encephalitis in young female)",
    "option_b": "Anti GLU",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Anti-NMDA receptor encephalitis is an autoimmune encephalitis most commonly seen in young females. The disease is characterized by a constellation of neuropsychiatric symptoms including seizures, psychosis, and cognitive dysfunction, and is often associated with an ovarian teratoma. The condition is mediated by IgG autoantibodies directed against the GluN1 subunit of NMDA receptors. Binding of these antibodies leads to receptor internalization and hypofunction, which disrupts normal synaptic transmission and results in neuropsychiatric manifestations. Clinical features often include a prodrome with fever, followed by psychiatric symptoms (such as psychosis and agitation), seizures, and abnormal movements. The syndrome is frequently recognized in young females and can be mistaken for primary psychiatric disorders if not carefully evaluated. Diagnosis is confirmed by detecting anti-NMDA receptor antibodies in the cerebrospinal fluid (and sometimes serum) along with supportive findings on MRI and EEG. Differential diagnoses include viral encephalitis (e.g., herpes simplex encephalitis), other autoimmune encephalitides (such as those associated with VGKC complex antibodies), and primary psychiatric disorders. Early and aggressive immunotherapy is critical. First-line treatments include high-dose steroids, IVIG, and plasmapheresis. In cases associated with an underlying tumor, surgical removal (e.g., teratoma resection) is imperative. Pregnancy and lactation considerations involve the use of steroids and IVIG, which are generally acceptable in pregnancy with careful monitoring, while the risks of teratogenicity must be weighed in the context of tumor removal and immunotherapy. Option A (Anti-NMDA) is correct because anti-NMDA receptor antibodies are the hallmark of this condition. Option B (Anti GLU) is not a recognized antibody in this context. 1. Always consider anti-NMDA receptor encephalitis in young females presenting with a mix of psychiatric symptoms, seizures, and movement disorders. 2. There is a strong association with ovarian teratomas necessitating tumor screening. 3. Early immunotherapy can significantly improve outcomes. Current guidelines and emerging research emphasize early detection and treatment of anti-NMDA receptor encephalitis. Recent studies have shown that prompt immunotherapy and tumor resection (when applicable) greatly improve neurological recovery and long-term outcomes.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "What\u2019s the cardinal feature of in case scenario suggestive of NMO?",
    "option_a": "Optic neuritis",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder that primarily affects the optic nerves and spinal cord. Its core clinical manifestations are severe optic neuritis and acute myelitis, often with longitudinally extensive spinal cord lesions. NMO is primarily mediated by anti\u2010Aquaporin4 (AQP4) antibodies. These antibodies target AQP4 water channels on astrocytes, leading to complement activation, astrocytic damage, and secondary demyelination. This mechanism distinguishes NMO from other demyelinating diseases like multiple sclerosis. Patients typically present with severe, often bilateral, optic neuritis marked by painful visual loss, as well as episodes of transverse myelitis that may lead to motor, sensory, and autonomic deficits. Recognition of optic neuritis as a cardinal feature is crucial for early suspicion of NMO. Diagnosis involves a combination of clinical findings, MRI (notably showing longitudinally extensive transverse myelitis in the spinal cord), and serological testing for anti-Aquaporin4 antibodies. Differential diagnoses include multiple sclerosis and other inflammatory myelopathies, but the pattern of optic neuritis combined with extensive myelitis is more typical for NMO. Acute attacks are typically managed with high-dose intravenous corticosteroids. If patients have an inadequate response, plasma exchange (PLEX) may be considered. Long-term management involves immunosuppressive therapies such as azathioprine or rituximab. In pregnant or lactating women, treatment options need to balance disease control with fetal safety; corticosteroids are often regarded as relatively safe in these settings, while other immunosuppressives may require careful risk-benefit analysis. Option A (Optic neuritis) is correct because optic neuritis is one of the two cardinal clinical features of NMO (the other being acute myelitis). Considering the limited options provided, recognizing optic neuritis as a foremost manifestation in a patient suspected of NMO is accurate. 1. Recurrent and severe optic neuritis, especially when bilateral, should heighten suspicion for NMO rather than multiple sclerosis. 2. Early recognition and treatment of NMO are essential to minimizing irreversible neurological damage. Recent guidelines emphasize the importance of anti-Aquaporin4 antibody testing in diagnosing NMOSD. Ongoing research into targeted therapies, such as new B-cell depleting agents, continues to refine long-term treatment strategies.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with bilateral optic neuritis + LETM, to confirm dx?",
    "option_a": "OCB",
    "option_b": "Aquaporin 4",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Neuromyelitis optica spectrum disorder (NMOSD) is characterized by a combination of bilateral optic neuritis and longitudinally extensive transverse myelitis, making the presence of these symptoms highly suggestive for the condition. The disease is mediated by anti-Aquaporin4 antibodies that target astrocytes, leading to complement-mediated cell injury and demyelination. This antibody-driven process differentiates NMOSD from multiple sclerosis and guides the diagnostic process. A clinical picture with bilateral optic neuritis and LETM strongly supports NMOSD. Patients typically experience severe visual impairment accompanied by motor and sensory deficits related to spinal cord involvement. Confirmation of NMOSD is achieved by demonstrating the presence of anti-Aquaporin4 antibodies in the serum. MRI findings further reinforce the diagnosis. The primary differential diagnosis is multiple sclerosis; however, Oligoclonal bands (OCBs) are more characteristic of MS, not NMOSD. Acute management involves high-dose corticosteroids to reduce inflammation, with plasma exchange reserved for steroid-refractory cases. Long-term management is centered on immunosuppression (e.g., rituximab, azathioprine) to prevent relapses. In pregnant and lactating patients, therapy must be individualized to minimize fetal risks while effectively controlling maternal disease. Option B (Aquaporin 4) is correct because testing for anti-Aquaporin4 antibodies is essential in confirming NMOSD. Option A (OCB) is more associated with multiple sclerosis and would not confirm NMOSD in the context of the presented clinical findings. 1. The combination of bilateral optic neuritis and LETM is highly indicative of NMOSD. 2. Serum aquaporin-4 antibody testing is the gold standard for confirming the diagnosis. Recent studies reinforce that aquaporin-4 antibody testing offers high specificity for NMOSD. Additionally, advances in targeted immunotherapies have improved relapse prevention and overall prognosis in these patients.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Female patient with MS on Natalizumab, PRESENTED with hemiparesis and hemianopia. MRI showed subcortical white matter mass with no enhancement. What will you do?",
    "option_a": "IVIG",
    "option_b": "METHYLPREDNISOLONE",
    "option_c": "PLEX (PML)",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Natalizumab is an immunomodulatory therapy used in multiple sclerosis that, due to its effects on immune surveillance in the central nervous system, increases the risk of developing progressive multifocal leukoencephalopathy (PML). PML is caused by the reactivation of the JC virus, a polyomavirus that infects oligodendrocytes leading to demyelination. In the context of natalizumab therapy, the compromised immune surveillance allows the virus to proliferate and cause brain lesions, typically in the subcortical white matter. Patients on natalizumab who develop new neurological deficits\u2014such as hemiparesis and hemianopia\u2014should be urgently evaluated for PML. The absence of contrast enhancement on MRI is characteristic for non-inflammatory PML lesions, distinguishing them from typical MS relapses. The diagnosis of PML is supported by MRI findings (non-enhancing subcortical lesions) and confirmed by the detection of JC virus DNA in the cerebrospinal fluid via PCR. Differential diagnoses include an MS relapse (which typically shows contrast-enhancing lesions) and other CNS infections. Immediate discontinuation of natalizumab is mandatory. Plasma exchange (PLEX) is used to accelerate the removal of natalizumab and restore immune surveillance. In the event of immune reconstitution inflammatory syndrome (IRIS), high-dose corticosteroids may be employed. In pregnant or lactating patients, the management of PML is particularly challenging, often necessitating a multidisciplinary approach to balance the risks of the drug with the health of both the mother and the fetus. Option C (PLEX) is correct because it is the standard intervention to accelerate the clearance of natalizumab and potentially reduce the progression of PML. Option A (IVIG) is not indicated for PML, and Option B (Methylprednisolone) is generally reserved for managing IRIS rather than the primary treatment for natalizumab-associated PML. 1. In natalizumab-treated patients, a new neurological deficit with non-enhancing white matter lesions should raise immediate concern for PML. 2. Early intervention with plasma exchange is crucial in halting the progression of PML. Current guidelines and studies support the early use of PLEX in the management of natalizumab-associated PML. Ongoing research continues to explore optimal strategies to manage and prevent IRIS following immune reconstitution.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Multiple Sclerosis Patient, asking about VEP finding",
    "option_a": "Prolong P100",
    "option_b": "Shorten P100",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Visual evoked potentials (VEPs) are electrophysiological tests that assess the functional integrity of the visual pathways. In multiple sclerosis (MS), VEP is used to detect demyelination within the optic nerve. MS leads to demyelination of central nervous system pathways, including the optic nerves. Demyelination results in slowed nerve conduction, which is manifested as a prolonged latency of the P100 wave in VEP studies. Even in cases where optic neuritis is subclinical, patients with MS often demonstrate a prolonged P100 latency. This finding supports the diagnosis of MS and correlates with the disease's demyelinating pathology. VEP testing is an ancillary diagnostic tool in the evaluation of suspected demyelinating disease. The typical finding in MS is a significant delay in the P100 wave latency. Differential diagnoses for abnormal VEPs include other causes of optic neuropathy; however, the characteristic delay seen in MS helps to differentiate it from conditions that might affect amplitude rather than latency. Although VEP findings do not change the overall management of MS, they provide supportive evidence for demyelination. The management of MS focuses on disease-modifying therapies such as beta-interferons, glatiramer acetate, or newer agents. Pregnancy and lactation require careful selection of treatments\u2014agents like interferon-beta have more established safety profiles compared to newer therapies. Option A (Prolong P100) is correct because MS typically causes demyelination that leads to delayed conduction in the visual pathways, manifesting as a prolonged P100 latency. Option B (Shorten P100) is not consistent with the demyelinating process seen in MS. 1. Prolongation of the P100 latency is a hallmark finding in VEP studies for patients with MS. 2. VEP abnormalities can be present even in the absence of overt clinical optic neuritis, making it a useful tool in supporting the diagnosis. Recent research and clinical guidelines continue to validate the use of VEP as an adjunct diagnostic tool in MS. Advances in electrophysiological techniques further refine its sensitivity in detecting subclinical demyelinating events.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Kid with MS symptoms: what is the Risk factor?",
    "option_a": "EBV",
    "option_b": "CMV",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system. Research has identified Epstein\u2010Barr virus (EBV) as one of the strongest environmental risk factors, particularly through its ability to trigger an abnormal immune response in genetically predisposed individuals. EBV infection is believed to contribute to MS pathogenesis through molecular mimicry and B-cell dysregulation. The virus may induce an immune response that cross\u2010reacts with CNS myelin antigens, thus promoting neuroinflammation and demyelination. Recent studies have solidified the association between EBV seropositivity and increased MS risk. Clinically, many patients with MS have serologic evidence of past EBV infection. While the diagnosis of MS is based on clinical and radiological criteria (eg, McDonald criteria), the underlying EBV exposure supports the understanding of MS as a multifactorial disease with infectious, genetic, and environmental components. MS is typically diagnosed using a combination of clinical evaluation, MRI findings (multifocal white matter lesions), and sometimes cerebrospinal fluid analysis. Although EBV serology may show past infection, it is not used to diagnose MS but rather to understand risk and epidemiological associations. Differential diagnoses include neuromyelitis optica spectrum disorder, acute disseminated encephalomyelitis, and other inflammatory or demyelinating conditions. While identifying risk factors is crucial in understanding disease etiology, management of MS centers on symptomatic relief during acute relapses (typically high-dose corticosteroids) and long-term disease-modifying therapies (DMTs) to reduce relapse frequency and disability progression. In pediatric patients, treatment choices are made cautiously with attention to developmental effects. For pregnant or lactating patients, interferon beta and glatiramer acetate are generally considered safer options, while other DMTs require individualized risk\u2013benefit assessments. Option A (EBV) is correct because numerous studies have demonstrated an association between EBV infection and increased risk of developing MS. Option B (CMV) has not been shown to be as strongly associated with MS. Options C and D were not provided. 1. Nearly all patients with MS are seropositive for EBV, highlighting its role as a risk factor. 2. Pediatric MS is rare, and when present, underlying risk factors like EBV exposure are important to note. Recent epidemiological and immunological studies have reinforced the EBV-MS link, prompting ongoing research into vaccines targeting EBV as a potential future preventive strategy for MS.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "MS case fulfilling criteria asked about next after acute management?",
    "option_a": "Observe",
    "option_b": "start treatment",
    "option_c": "do MRI after 3 months",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Once an MS diagnosis is established by fulfilling the diagnostic criteria (eg, McDonald criteria), management involves both treating acute relapses and initiating long-term disease-modifying therapy (DMT) to reduce future relapse activity and delay disability progression. The underlying disease process in MS involves autoimmune-mediated inflammation leading to demyelination and axonal injury. After an acute relapse (often managed with high-dose intravenous corticosteroids), persistent inflammatory activity necessitates the initiation of DMT to modify the disease course. Patients who experience an acute relapse typically present with neurological deficits (visual, sensory, or motor) that correlate with new demyelinating lesions on MRI. Early initiation of DMT has been shown to reduce relapse frequency and long-term disability. After acute management, the focus shifts to definitive diagnosis and long-term management. Differential diagnoses considered earlier include other demyelinating conditions like neuromyelitis optica or acute disseminated encephalomyelitis; however, once MS is confirmed, the emphasis is on modifying disease activity. First-line management post-acute relapse involves starting a DMT, such as interferon-beta, glatiramer acetate, or newer agents if indicated by disease activity. In pregnant patients, certain DMTs (eg, interferon-beta or glatiramer acetate) may be continued based on current guidelines, whereas others are generally avoided. The tiered approach is typically: 1) initiate first-line agents; 2) if breakthrough disease occurs, escalate therapy to higher efficacy treatments; 3) monitor with serial MRI. Option A (Observe) is not appropriate because delaying treatment may allow further disease activity. Option B (Start treatment) is correct because initiating a DMT is recommended after acute management to suppress ongoing inflammation. Option C (Do MRI after 3 months) may be used as a monitoring tool later but does not address the need for immediate disease-modifying intervention. 1. Timely initiation of DMT in MS is essential to minimize future relapses and long-term disability. 2. MRI is crucial for both initial diagnosis and subsequent monitoring, but treatment should not be delayed awaiting imaging. Current guidelines emphasize early treatment of MS with DMTs following the first clinically isolated syndrome or definitive diagnosis to improve long-term outcomes. Ongoing research continues to refine the optimal timing and choice of therapy.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Young female with RRMS on Interferon, came with***. MRI showed multiple enhancements white matter lesions, what to do next.",
    "option_a": "start Natalizumab",
    "option_b": "Continue Interferon",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "In patients with relapsing-remitting MS (RRMS) who are already on a first-line DMT (such as interferon-beta), evidence of breakthrough disease\u2014in the form of new clinical symptoms or new enhancing lesions on MRI\u2014should prompt an evaluation for treatment escalation. Breakthrough lesions on MRI indicate ongoing inflammatory activity despite current therapy. This suggests that the immunomodulatory effect of interferon may be insufficient in suppressing the aberrant immune response, leading to continued demyelination and axonal injury. A young female with RRMS on interferon presenting with new neurological symptoms and multiple enhancing white matter lesions on MRI is displaying signs of active disease. Such radiologic findings correlate with disease relapse and increased future disability if not adequately controlled. The diagnostic workup involves confirming that the new lesions are indeed due to MS activity and not due to other confounding factors (eg, infection, other demyelinating conditions). Differential diagnoses include pseudorelapse, other central nervous system inflammatory conditions, or even imaging artefacts. A thorough clinical and radiologic evaluation is essential. For patients with breakthrough disease while on interferon, the recommended approach is to escalate to a higher efficacy DMT. Natalizumab is one such agent known for its robust efficacy in reducing relapse rates and MRI activity. In pregnant patients or those planning pregnancy, natalizumab requires careful review (typically Category C) and a risk-benefit discussion, as some newer evidence suggests it may be used in selected high-risk cases with close monitoring. Alternative options in women of childbearing potential include interferon or glatiramer acetate, depending on risk profiles and disease severity. Option A (Start Natalizumab) is correct because escalation to a higher efficacy agent is warranted in the presence of breakthrough disease. Option B (Continue Interferon) is inappropriate given the evidence of active disease. Options C and D were not provided. 1. The presence of new enhancing lesions on MRI while on DMT suggests treatment failure and the need for escalation. 2. Early identification of breakthrough disease is critical to prevent cumulative neurological disability. Recent clinical trials and long-term observational studies have demonstrated that early treatment escalation in patients with active RRMS reduces relapse rates and may slow disability progression. Ongoing studies continue to refine the strategies for selecting the best tailored high efficacy therapy for individual patients.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Male patient with limbic encephalitis (seizures, psychosis\u2026) asked about ab?",
    "option_a": "Anti NMDA",
    "option_b": "anta glutamate",
    "option_c": "anti-glycine.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Limbic encephalitis is an autoimmune inflammatory process affecting the medial temporal lobes, resulting in symptoms such as seizures, memory impairment, and psychiatric manifestations. Autoantibodies play a critical role in its pathogenesis, with anti-NMDA receptor antibodies being one of the well-known culprits. Anti-NMDA receptor encephalitis involves autoantibodies that target the NMDA receptors on neurons, leading to receptor internalization and subsequent disruption of glutamatergic neurotransmission. This immune-mediated attack results in a constellation of neuropsychiatric symptoms. Although the syndrome predominantly occurs in young women (often associated with ovarian teratomas), males can also be affected. Clinically, patients with anti-NMDA receptor encephalitis present with a combination of psychiatric symptoms (psychosis, agitation), seizures, memory deficits, and sometimes movement disorders. In a male patient, while other antibodies (like anti-GABA_B receptor) can also be considered, the clinical picture provided aligns well with anti-NMDA receptor encephalitis. Diagnosis is achieved through a combination of clinical evaluation, MRI (which may show medial temporal lobe involvement), and the detection of specific autoantibodies in serum and cerebrospinal fluid. Differential diagnoses include viral encephalitis (eg, herpes simplex encephalitis), other forms of autoimmune encephalitis (eg, anti-LGI1 encephalitis), and metabolic or toxic encephalopathies. First-line treatment for anti-NMDA receptor encephalitis involves immunotherapy (high-dose corticosteroids, intravenous immunoglobulin, or plasmapheresis) to attenuate the autoimmune response. If the response is inadequate, second-line treatments like rituximab or cyclophosphamide may be considered. In pregnant or lactating women, treatment decisions weigh fetal safety\u2014IVIG and corticosteroids are generally preferred over cytotoxic agents, but each case must be individualized. Option A (Anti NMDA) is correct as anti-NMDA receptor antibodies are the most recognized cause of autoimmune encephalitis presenting with limbic system involvement. Option B (anta glutamate) is not standard nomenclature and might be misleading if referring to anti-AMPA receptor antibodies, which are less common in this clinical context. Option C (anti-glycine) is not typically associated with limbic encephalitis. 1. Although anti-NMDA receptor encephalitis is more common among young females, it can also affect males. 2. Early recognition and prompt immunotherapy significantly improve outcomes in autoimmune encephalitis. Recent advances in neuroimmunology have underscored the importance of early antibody testing in suspected autoimmune encephalitis, with emerging evidence supporting the effectiveness of early therapeutic interventions using immunomodulatory strategies. Ongoing research continues to elucidate the spectrum of autoantibodies involved and their optimal management.",
    "exam_year": "2021",
    "exam_type": "Part I"
  }
]